{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:50:01Z","timestamp":1792457401250,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005036","name":"University of Bergen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005036","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejim.2025.106459","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T16:04:08Z","timestamp":1755619448000},"page":"106459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Effectiveness and safety of rituximab across the four phenotypes of IgG4-related disease: a European multi-center cohort study"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3094-9968","authenticated-orcid":false,"given":"Elisabetta","family":"Goni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9045-3588","authenticated-orcid":false,"given":"Jens","family":"Vikse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4522-2921","authenticated-orcid":false,"given":"Marco","family":"Lanzillotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6957-8730","authenticated-orcid":false,"given":"Bj\u00f8rg-Tilde Svanes","family":"Fevang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8yvind","family":"Midtvedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7134-1224","authenticated-orcid":false,"given":"Jasmin","family":"Mahajne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Batani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Benanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7607-8264","authenticated-orcid":false,"given":"Georg","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7428-315X","authenticated-orcid":false,"given":"Lorenzo","family":"Dagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8yvind","family":"Molberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3770-8139","authenticated-orcid":false,"given":"Katrine Br\u00e6kke","family":"Norheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3266-9791","authenticated-orcid":false,"given":"Ulf","family":"Sch\u00f6nermarck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivonne","family":"Regel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3666-6459","authenticated-orcid":false,"given":"Julia","family":"Mayerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Hoffmann-Vold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Della-Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2025.106459_bib0001","doi-asserted-by":"crossref","first-page":"m1067","DOI":"10.1136\/bmj.m1067","article-title":"Advances in the diagnosis and management of IgG4 related disease","author":"Lanzillotta","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ejim.2025.106459_bib0002","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1146\/annurev-med-050219-034449","article-title":"Clinical perspectives on IgG4-related disease and its classification","volume":"73","author":"Katz","year":"2022","journal-title":"Annu Rev Med"},{"issue":"2","key":"10.1016\/j.ejim.2025.106459_bib0003","article-title":"Current and future advances in practice: IgG4-related disease","volume":"8","author":"Wallace","year":"2024","journal-title":"Rheumatol Adv Pract"},{"issue":"2","key":"10.1016\/j.ejim.2025.106459_bib0004","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/mr\/roac097","article-title":"Glucocorticoids in the treatment of IgG4-related disease\u2014prospects for new international treatment guidelines","volume":"33","author":"Yoshifuji","year":"2023","journal-title":"Mod Rheumatol"},{"issue":"2","key":"10.1016\/j.ejim.2025.106459_bib0005","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/mr\/roac098","article-title":"B-cell depletion therapy in IgG4-related disease: state of the art and future perspectives","volume":"33","author":"Lanzillotta","year":"2023","journal-title":"Mod Rheumatol"},{"issue":"7","key":"10.1016\/j.ejim.2025.106459_bib0006","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.pan.2021.06.009","article-title":"Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: a systematic review and meta-analysis","volume":"21","author":"Lanzillotta","year":"2021","journal-title":"Pancreatology"},{"issue":"12","key":"10.1016\/j.ejim.2025.106459_bib0007","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.cgh.2018.02.049","article-title":"Rituximab maintenance therapy reduces rate of relapse of pancreaticobiliary immunoglobulin G4-related disease","volume":"16","author":"Majumder","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.ejim.2025.106459_bib0008","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","article-title":"Rituximab for IgG4-related disease: a prospective, open-label trial","volume":"74","author":"Carruthers","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.ejim.2025.106459_bib0009","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMoa2409712","article-title":"Inebilizumab for treatment of IgG4-related disease","volume":"392","author":"Stone","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejim.2025.106459_bib0010","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/annrheumdis-2018-214603","article-title":"Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts","volume":"78","author":"Wallace","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ejim.2025.106459_bib0011","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1093\/rheumatology\/keaa221","article-title":"Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes","volume":"59","author":"Lanzillotta","year":"2020","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.ejim.2025.106459_bib0012","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/annrheumdis-2019-216561","article-title":"The 2019 American college of rheumatology\/european league against rheumatism classification criteria for IgG4-related disease","volume":"79","author":"Wallace","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ejim.2025.106459_bib0013","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-023-03155-y","article-title":"Differential sensitivity of the 2020 revised comprehensive diagnostic criteria and the 2019 ACR\/EULAR classification criteria across IgG4-related disease phenotypes: results from a Norwegian cohort","volume":"25","author":"Vikse","year":"2023","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.ejim.2025.106459_bib0014","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/rheumatology\/key285","article-title":"Mortality and causes of death across the systemic connective tissue diseases and the primary systemic vasculitides","volume":"58","author":"Garen","year":"2019","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.ejim.2025.106459_bib0015","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/14397595.2020.1859710","article-title":"The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD","volume":"31","author":"Umehara","year":"2021","journal-title":"Mod Rheumatol"},{"issue":"11","key":"10.1016\/j.ejim.2025.106459_bib0016","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/acr.23543","article-title":"An international multispecialty validation study of the IgG4-related disease responder index","volume":"70","author":"Wallace","year":"2018","journal-title":"Arthritis Care Res"},{"issue":"7","key":"10.1016\/j.ejim.2025.106459_bib0017","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/S2665-9913(23)00299-0","article-title":"Fibrotic phenotype of IgG4-related disease","volume":"6","author":"Lanzillotta","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"10.1016\/j.ejim.2025.106459_bib0018","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2665-9913(24)00022-5","article-title":"Proliferative features of IgG4-related disease","volume":"6","author":"Katz","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"42","key":"10.1016\/j.ejim.2025.106459_bib0019","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012631","article-title":"Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis","volume":"97","author":"Wallwork","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.ejim.2025.106459_bib0020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejim.2024.06.006","article-title":"Efficacy and safety of rituximab induction therapy and effect of rituximab maintenance for IgG4-related disease: a systematic review and meta-analysis","volume":"127","author":"Liu","year":"2024","journal-title":"Eur J Intern Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525003371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525003371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:26:08Z","timestamp":1772825168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620525003371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":20,"alternative-id":["S0953620525003371"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2025.106459","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of rituximab across the four phenotypes of IgG4-related disease: a European multi-center cohort study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2025.106459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106459"}}